Blackford at RSNA 2021: It’s Time to Realize the Value of AI

World’s broadest AI imaging marketplace enables unbiased navigation of medical imaging AI to identify the best-suited applications, measure their potential, and realize the value that they can deliver

Blackford Analysis, the platform for medical imaging applications and AI, today unveiled its latest vision at RSNA 2021. The platform now provides a standardized, unbiased approach to the largest number of medical imaging AI algorithms on the market.

Through Blackford’s curated market of integrated AI applications, healthcare organizations can identify the applications best suited to their organization, measure their potential, roll them out, and realize the value that they can deliver. Serving more than 750 sites across the world, the platform currently provides access to 56 regulatory cleared clinical applications, with more joining every month.

Blackford will be showcasing several exciting new AI applications at RSNA that are now available on its platform, as well as highlighting key new partnerships with 3M Health Information Systems, Bialogics and EBIT, Esaote.

3M M*Modal Fluency for Imaging combines advanced speech recognition technology, computer-assisted physician documentation (CAPD) for real-time clinical insights, information-enabled workflow management and productivity-enhancing tools.

Bialogics identifies, extracts, and correlates data from diagnostic reports to provide analysis of AI/ML algorithms AI analysis to unlock clinical and operational insights hidden within discrete and narrative data elements.

Ebit, Esaote Group integrates within the Blackford RIS-CVIS PACS environment, allowing enhanced clinical solutions to physicians.

“When navigating the AI landscape, nothing is more important than access to a broad offering of applications from a platform provider who is free of clinical bias and has a history of success in delivery within the AI marketplace space,” said Ben Panter, CEO, Blackford. “We originated the AI marketplace concept and offer the broadest integrated suite of medical imaging in the market today. As the leading marketplace provider, we believe in integrity and the opportunity to navigate without risk and bias.”

Navigate the market

Blackford’s unbiased, open vendor approach provides access to the widest selection of regulatory cleared medical imaging AI applications and allows any application on the market to be quickly added – including those developed in-house.

“Our established frameworks allow healthcare organizations to determine the most accurate and valuable solutions with a fraction of the IT and clinical resources when compared to any other marketplaces or direct interactions with AI vendors,” said Panter.

Measure the potential

The platform allows providers to accelerate the evaluation process of any given AI algorithm by providing tools to dramatically compress the time and investment required to assess and quickly determine their appropriateness and applicability.

“We use evidence to help define our customers’ AI strategy and avoid time-consuming trial-and-error attempts, while reducing the internal and external costs of AI evaluation,” said Panter.

Realize the value

But the ultimate goal of Blackford’s dedicated platform is to help healthcare organizations realize and enhance the value of medical imaging AI applications over time – delivering economies of scale to magnify the benefits.

“We do this by quickly and easily deploying applications, innovating the workflow integrations, orchestration and tools required, and continually measuring application performance as the AI market develops,” said Panter. “We enable the clarity of an algorithm’s value and performance over time, providing greater confidence for the continuation of program funding and long-term application utilization.”

Also, at RSNA this year, on Wednesday, December 1st, at 11:30 a.m. CST Blackford CEO Ben Panter will deliver an Industry Presentation entitled What’s Holding AI Back? The presentation will address the key challenges that must be overcome to make AI a commercial success in medical imaging.

More here.

SourceBlackford

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”